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Significance of this study
What is already known on this subject?
 ► Glial cell line-derived neurotrophic factor 
(GDNF) is a member of the transforming 
growth factor-β superfamily and an important 
player in neuronal survival.
 ► GDNF ligands canonically signal by binding to 
glycosyl-phosphatidylinositol (GPI)-anchored 
receptors, termed GDNF family receptor alpha-1 
(GFRα1), in collaboration with signalling 
receptor subunits, such as the Ret tyrosine 
kinase.
What are the new findings?
 ► GDNF in the serum increased significantly in 
human liver fibrosis compared with healthy 
controls.
 ► Serum levels of GDNF are positively associated 
with hepatic stellate cell (HSC) activation and 
liver fibrosis progression.
 ► GDNF promotes HSC activation through activin 
receptor-like kinase 5 at His39 and Asp76 and 
downstream signalling via Smad2/3, but not 
through GFRα1.
 ► Mice with overexpression of GDNF display 
aggravated liver fibrosis, while mice with 
silenced GDNF expression or treated with 
GDNF-blocking antibodies have reduced fibrosis 
and HSC activation in carbon tetrachloride and 
bile duct ligation (BDL) disease models.
How might it impact on clinical practice in the 
foreseeable future?
 ► GDNF upregulation presents as a new 
biomarker for HSC activation and liver fibrosis 
progression that is measurable in blood and 
thus has potential for clinical diagnosis of liver 
fibrosis; moreover, inhibition of GDNF can be 
developed as novel therapeutic approach for 
liver fibrosis.
AbSTrACT
Objective although glial cell line-derived neurotrophic 
factor (gDnF) is a member of the transforming growth 
factor-β superfamily, its function in liver fibrosis has 
rarely been studied. Here, we investigated the role of 
gDnF in hepatic stellate cell (HSc) activation and liver 
fibrosis in humans and mice.
Design gDnF expression was examined in liver biopsies 
and sera from patients with liver fibrosis. the functional 
role of gDnF in liver fibrosis was examined in mice with 
adenoviral delivery of the gDnF gene, gDnF sgrna 
criSPr/cas9 and the administration of gDnF-blocking 
antibodies. gDnF was examined on HSc activation using 
human and mouse primary HScs. the binding of activin 
receptor-like kinase 5 (alK5) to gDnF was determined 
using surface plasmon resonance (SPr), molecular 
docking, mutagenesis and co-immunoprecipitation.
results gDnF mrna and protein levels are significantly 
upregulated in patients with stage F4 fibrosis. Serum 
gDnF content correlates positively with α-smooth 
muscle actin (α-SMa) and col1a1 mrna in human 
fibrotic livers. Mice with overexpressed gDnF display 
aggravated liver fibrosis, while mice with silenced gDnF 
expression or signalling inhibition by gDnF-blocking 
antibodies have reduced fibrosis and HSc activation. 
gDnF is confined mainly to HScs and contributes to HSc 
activation through alK5 at His39 and asp76 and through 
downstream signalling via Smad2/3, but not through 
gDnF family receptor alpha-1 (gFrα1). gDnF, alK5 
and α-SMa colocalise in human and mouse HScs, as 
demonstrated by confocal microscopy.
Conclusions gDnF promotes HSc activation and liver 
fibrosis through alK5/Smad signalling. inhibition of 
gDnF could be a novel therapeutic strategy to combat 
liver fibrosis.
InTrODuCTIOn
Liver fibrosis, which is characterised by excessive 
extracellular matrix (ECM) deposition, results from 
chronic liver injury of different aetiologies and 
represents a major health problem worldwide.1–3 
The progression of liver fibrosis to cirrhosis gives 
rise to severe complications including portal hyper-
tension, liver failure and hepatocellular carcinoma.4 
Hepatic stellate cells (HSCs) reside in the space of 
Disse in the liver,5 and on liver injury, quiescent 
HSCs undergo a phenotypic and metabolic switch 
that leads to the acquisition of a myofibroblast 
(MFB)-like phenotype. Such HSC-derived MFBs 
are the predominant liver cell type that produces 
ECM in response to various damaging insults.6 7 
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Moreover, activated HSCs release cytokines and chemokines and 
express specific receptors, allowing them to communicate with 
other liver cells.8 Thus, inhibition of HSC activation is proposed 
as a therapeutic strategy for patients with liver fibrosis.9 10 The 
HSC activation process is induced by various stimulatory factors, 
including transforming growth factor beta 1 (TGFβ1).11 TGFβ1 
is a potent profibrogenic cytokine due to its role in HSC activa-
tion. In this regard, TGFβ and its downstream targets have been 
implicated in both animal models and patients. However, interest 
in the use of anti-TGFβ biological agents has been significantly 
tempered by reports of serious adverse effects.12 
Glial cell line-derived neurotrophic factor (GDNF), as a glyco-
sylated, disulfide-bonded homodimer, is a member of the TGFβ 
superfamily.13 The contributions of GDNF have been described 
in renal morphogenesis14 and spermatogonial cell develop-
ment.15 GDNF exerts a critical function in the peripheral taste 
system.16 GDNF is currently being evaluated for the treatment of 
Parkinson’s disease in humans.17 GDNF family signalling path-
ways ligands are involved in the pathogenesis of bone pain and 
could be targeted for pharmacological intervention.18 GDNF was 
identified as a key determinant of resistance to aromatase inhib-
itor therapy in oestrogen receptor-positive breast cancer.19 In the 
canonical signalling pathway, GDNF binds to a GDNF family 
receptor (GFRα) in conjunction with Ret tyrosine kinase.20–22 
Inverse effects of GFR and Ret in the context of vitamin D stim-
ulation have also been reported.23 Chen et al demonstrated that 
p75 interacts with Ret and GFRα1 on stimulation with GDNF.24 
However, the molecular mechanisms underlying GDNF-medi-
ated HSC activation and liver fibrosis remain unknown.
We hypothesised that GDNF induces HSC activation and 
liver fibrosis through the activin receptor-like kinase 5 (ALK5)/
Smad pathway. Therefore, we examined the role of GDNF/Smad 
signalling in HSC activation and provide proof of concept of this 
pathway as a therapeutic target.
MATerIAlS AnD MeTHODS
Patient samples and clinical data information
The study conforms with the provisions of the Declaration of 
Helsinki.
Serum samples collected from 157 healthy controls (HCs) at 
Putuo Hospital (December 2017 to April 2018) and from 239 
patients with liver biopsy (F0=25, F1=48, F2=87, F3=51, 
F4=28; June 2011 to July 2018) were used for GDNF concen-
tration measurement. GDNF mRNA expression was investigated 
in 165 patients (F0=13, F1=35, F2=61, F3=40, F4=16) who 
underwent liver biopsies between February 2013 and July 2018. 
GDNF protein expression was examined in 21 fibrotic tissue 
samples (F0=3, F1=6, F2=6, F3=6, F4=3). The aetiological 
background of patients was chronic hepatitis B. Fibrosis stages 
were defined based on Scheuer criteria.25
Liver biopsy samples of patients with non-alcoholic fatty liver 
disease (NAFLD) were collected from May 2014 to June 2018 
in Shanghai General Hospital, Jiao Tong University School of 
Medicine. Pathologists examined the specimens and determined 
degree of fat, lobular/portal inflammation, hepatocyte ballooning 
and fibrosis stages. Controls (F0) were obtained from patients 
with NAFLD without fibrosis on biopsies. Paraffin liver sections 
(F0/1=7; F2=7; F3/4=5) were used for histology examination 
and GDNF staining, frozen liver samples (F0/1=11; F2/3=7) 
for GDNF mRNA analyses.
Serum samples of patients with alcoholic hepatitis (AH) or 
alcoholic cirrhosis (AC) were collected from October 2017 to 
July 2018 in Putuo Hospital, Shanghai University of Traditional 
Chinese Medicine, excluding patients with evidence of other 
liver diseases, based on standard clinical, laboratory and histo-
logical assessments. AC diagnosis was defined as chronic heavy 
alcohol consumption with portal hypertension, estimated by CT, 
causing variceal bleeding, ascites and hepatic encephalopathy.26 27 
Patients were not biopsied but characterised as having histolog-
ical stage F4 based on imaging. Written informed consent was 
obtained from all patients.
Surface plasmon resonance
To determine the binding of ALK5 to immobilised GDNF, we 
used a BIAcore T200 instrument (GE Healthcare) with a CM5 
sensor chip (GE Healthcare). The activation, deactivation and 
preparation of the coupled flow cell as well as the ligand-binding 
assay were performed essentially as described previously.28 
Briefly, GDNF in sodium acetate buffer (1 µg/mL, pH 5.5) was 
immobilised on a CM5 sensor chip, and ALK5 was analysed at a 
series of concentrations. The experiments were conducted with 
phosphate buffer saline, and the analyte was injected at a flow 
rate of 30 µL/min. The association time was 120 s, and the disso-
ciation time was 420 s. The binding constant was obtained using 
a 1:1 Langmuir binding model via a BIAcore evaluation software 
program.
Other methods and statistical analyses are described in online 
supplementary materials.
reSulTS
Patient characteristics
As shown in table 1, F4 stage patients had higher alanine trans-
aminase (ALT) and aspartate transaminase (AST) levels and 
lower platelet levels than HCs and F0 stage patients (p<0.05). 
F4 stage patients had significantly higher levels of hyaluronic 
acid and collagen IV than F0 stage patients (p<0.01). Other 
patient characteristics are summarised in table 1. NAFLD and 
alcoholic liver disease (ALD) patient information is included in 
online supplementary supporting table 1 and 2.
GDnF expression in patients with liver fibrosis and mouse 
models of liver fibrosis
GDNF concentrations were examined in 366 serum samples 
(127 HCs and 239 patients with liver fibrosis) using ELISA. 
Prominent increase in GDNF levels was evident in F4 patients 
compared with HC and F0–F2 patients (p<0.01; figure 1A). 
In addition, GDNF levels in human serum samples correlated 
significantly with the F stage (online supplementary supporting 
figure 1A, r=0.8137, p<0.0001).
GDNF mRNA expression was significantly higher in F3 
and F4 stages than in F0 patients (p<0.001), as determined in 
165 patients (figure 1B). GDNF concentrations in serum posi-
tively correlated with GDNF mRNA levels in liver (figure 1C, 
r=0.7250, p<0.0001). A positive correlation was observed 
between GDNF mRNA expression and F stage in livers of 
patients (online supplementary supporting figure 1A, r=0.5490; 
p<0.0001). We also tested HSC activation and collagen produc-
tion at mRNA levels (online supplementary supporting figure 
1B). α-SMA and Col1A1 mRNA expression increased with 
disease progression (F3 and F4 compared with F0; p<0.001). 
Because GDNF mRNA levels coincided with α-SMA levels, we 
evaluated these values in each patient with liver fibrosis and 
found a positive correlation (figure 1D, r=0.7837, p<0.0001). 
GDNF levels in serum also significantly correlated with α-SMA 
(r=0.8409, p<0.0001) and Col1A1 (r=0.8345, p<0.0001) 
expression in liver (online supplementary supporting figure 1C).
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Table 1 HBV patient characteristics
Variable
HC
n=127
F0
n=25
F1
n=48
F2
n=87
F3
n=51
F4
n=28 P value
Age (years) 39.3±10.6 38.5±7.5 40.0±11.2 40.8±11.4 43.5±11.8 42.3±10.9 0.2134
Gender (F/M) 78/49 13/12 17/31 36/51 14/37 7/21 0.0001
ALT (U/L) 12.8±9.26 49.0±67.3 73.4±124.2 135.8±207.5*** 169.8±209.9***### 181.0±339.4***### 0.0001
AST (U/L) 20.1±6.8 39.8±33.2 64.4±100.6 95.4±169.5*### 133.6±171.4**### 164.0±278.8***### 0.0001
Cr (μmol/L) 64.71±12.41*** 66.64±15.44### 70.48±13.54### 69.75±14.50### 79.74±25.58*### 69.89±12.47### 0.0001
BUN (mmol/L) 3.80±1.02* 3.88±1.08# 4.99±1.40### 4.48±1.48### 4.62±1.10### 4.78±0.87### 0.0001
HBV DNA
(log10IU/mL)
ND 4.90±2.13 4.62±1.91 5.15±2.29 4.91±2.16 5.27±1.68 0.5185
RBC (1012/L) 4.71±0.53 4.54±0.62 4.83±0.61 5.03±3.37 4.78±0.52 4.53±0.54 0.1505
WBC (109/L) 6.17±1.67 5.25±1.33 5.82±1.51 5.69±1.57 5.40±1.49# 5.01±1.61## 0.0004
PLT (109/L) 233.8±51.50*** 182.9±52.40### 195.7±62.54### 192.4±57.09### 159.4±54.37### 145.0±41.74**### 0.0001
HA (ng/mL） ND 31.92±30.19 79.79±110.3 117.3±169.7** 158.0±214.7*** 261.1±298.9*** 0.0001
PCIII (ng/mL） ND 11.85±8.87 8.11±5.53 9.45±15.23 10.79±7.93 14.16±8.20 0.0001
LN (ng/mL） ND 74.49±37.11 53.14±51.78 49.99±42.32 67.22±61.70 79.90±58.53 0.0034
CIV (ng/mL） ND 41.51±38.85 52.27±53.32 73.80±100.4 93.93±99.62** 206.4±238.5*** 0.0001
#P<0.05, ##p<0.01, ###p<0.001 compared with healthy controls. *p<0.05, **p<0.01, ***p<0.001 compared with F0 stage patients.
ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; CⅣ, collagen Ⅳ; Cr, serum creatinine; HA, hyaluronic acid; LN, laminin; PCⅢ, procollagen 
type Ⅲ; RBC, red blood cell; WBC, white blood cell; PLT, platelet.
Localisation of GDNF was determined by immunohistochem-
istry (figure 1E) and positive staining was evident in the hepatic 
sinusoids of patients with mild liver fibrosis. With increasing 
disease severity, GDNF-positive cells were also found in portal 
areas and adjacent to fibrotic septa (online supplementary 
supporting figure 1D).
Similar to our observations in viral hepatitis, non-alcoholic 
steatohepatitis (NASH)-induced liver fibrosis also presented with 
increased GDNF expression (figure 1F–H). Finally, ELISA data 
from patients with ALD show increased GDNF serum levels in 
patients with advanced cirrhosis compared with HC and patients 
with AH (p<0.01; figure 1I).
mRNA data were validated by immunoblotting for protein 
expression. Band intensities for GDNF and α-SMA are increasing 
with disease severity (online supplementary supporting figure 
1E), and showed a positive correlation (r=0. 8478, p<0.0001). 
Increasing numbers of α-SMA-positive and GDNF-positive cells 
colocalised along with fibrosis progression (online supplemen-
tary supporting figure 2), as evidenced using sequential (serial 
sections) or dual immunohistochemistry.
We next investigated mouse models of liver fibrosis, namely 
carbon tetrachloride (CCl4) for 6 weeks, BDL for 2 weeks, 
methionine-choline-deficient diet (MCD) for 8 weeks, and high 
fat diet (HFD) for 14 weeks. GDNF was present throughout 
in non-parenchymal cells of fibrotic livers (figure 2A). GDNF 
mRNA (figure 2B) and protein levels were increased with fibrosis 
progression (online supplementary supporting figure 3A and B). 
GDNF serum concentration increased significantly in fibrotic 
mice compared with control mice (p<0.01; online supplemen-
tary supporting figure 3C).
GDnF overexpression aggravates experimental liver fibrosis
To determine the functional impact of GDNF on liver fibrosis 
development, mice exposed to CCl4 were injected with an 
adenovirus expressing GDNF (Ad-GDNF) and a corresponding 
mock control. GDNF overexpression enhanced the architec-
tural disturbance and collagen deposition in CCl4-treated 
mice (figure 3A and B). Ectopic GDNF expression clearly 
increased collagen deposition and α-SMA expression, as 
determined by Sirius red staining and immunohistochemistry 
(figure 3B-3D). Furthermore, ALT and AST levels in serum 
increased in control and CCl4-treated mice with ectopic 
GDNF expression, indicating GDNF-mediated hepato-
cyte damage (figure 3E). mRNA levels of pro-inflammatory 
markers and chemokines, for example, Cd68 and Ccl2, are 
increased in Ad-GDNF treatment groups (figure 3F). GDNF 
overexpression also increased gene expression of fibrogenic 
parameters α-Sma, Mmp2, Timp1 and Col1α1 (figure 3G) in 
CCl4-treated mice and controls.
Results from CCl4 mice were confirmed in BDL mice. 
Ad-GDNF infection augmented BDL-induced liver fibrosis, as 
evident from histopathology of H&E and Sirius red staining, 
and α-SMA immunohistochemistry (supplementary supporting 
figure 4A-D). Serum ALT and AST levels were slightly increased, 
Cd68, α-Sma mRNA and profibrogenic gene expression were 
upregulated (online supplementary supporting figure 4E-G).
GDnF knockdown ameliorates experimental liver fibrosis
To further investigate the role of endogenous GDNF in 
hepatic fibrosis, CCl4 intoxication and BDL mouse models 
were subjected to Gdnf sgRNA CRISPR/Cas9 adenovirus 
delivery to deplete GDNF expression. GDNF expression in 
fibrotic livers was examined by immunoblotting and immu-
nohistochemistry (online supplementary supporting figure 
5A, B, 6A and B). Sirius red and α-SMA staining revealed 
attenuation of fibrosis and collagen deposition in CCl4 mice 
on Gdnf depletion, as compared with scrambled sgRNA 
treatment (online supplementary supporting figure 5B-D and 
6B-D). Moreover, mRNA levels of α-Sma and Col1α1 were 
significantly downregulated in Gdnf sgRNA/CCl4 mice in 
comparison to control CCl4 mice.
GDnF is profibrogenic and promotes HSC activation
To identify the cell type responsible for GDNF expression 
in liver fibrosis, we isolated the different cell types from 
human livers. GDNF mRNA was expressed at higher levels 
in HSCs than hepatocytes, Kupffer cells (KCs) or liver sinu-
soid endothelial cells (LSECs; figure 4A). GDNF mRNA 
expression was also higher in LX2 than HepG2, Huh7 or 
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Figure 1 Glial cell line-derived neurotrophic factor (GDNF) expression in liver fibrosis. (A) GDNF concentrations in 366 human serum samples 
measured by ELISA (healthy control (HC)=127; F0=25; F1=48; F2=87; F3=51; F4=28). (B) GDNF mRNA in 165 human liver specimens examined 
by real-time PCR. The levels of target mRNAs were normalised to that of 18S rRNA (F0=13; F1=35; F2=61; F3=40; F4=16). (C) Correlation analysis 
between GDNF concentrations in the serum and GDNF mRNA expression. Spearman's correlation coefficients (r), p values and the number of 
patients are indicated. (D) Correlation analysis between GDNF and α-SMA mRNA expression. Spearman's correlation coefficients (r), p values and 
the number of patients are indicated. (E) Immunohistochemistry of GDNF in frozen liver sections of 40 HBV patient samples (F0/1=10; F2=10; 
F3=10; F4=10). Upper original magnification x100, middle x600, lower x600, negative control; the red arrow indicates GDNF-positive staining. (F) 
Immunohistochemistry of GDNF in liver paraffin sections of non-alcoholic steatohepatitis (NASH) patient samples (F0/1=7; F2=7; F3/4=5). Upper 
original magnification x100, middle x600, lower x600, negative control; the red arrow indicates GDNF-positive staining. (G) Semiquantification of 
GDNF from figure 1F. (H) Hepatic GDNF mRNA expression in patients with NASH. (I) GDNF concentrations in serum samples from 30 HCs and 37 
patients with alcoholic liver disease (ALD), as measured by ELISA (HC=30; alcoholic hepatitis (AH)=26; alcoholic cirrhosis (AC)=11). Bars indicate the 
mean±SD of three independent experiments; one-way analysis of variance with the non-parametric Kruskal-Wallis test was used in A, B, G–I. A non-
parametric correlation (Spearman's) two-tailed test was used in C and D.
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Figure 2 Glial cell line-derived neurotrophic factor (GDNF) is upregulated in mouse liver fibrosis. (A) Representative images of GDNF staining in 
mouse liver fibrosis from carbon tetrachloride (CCl4), BDL, methionine-choline-sufficient (MCS), methionine-choline-deficient (MCD), normal chow diet 
(NCD), high fat diet (HFD) samples. Original magnification x100, the third line is x600, fourth line is the negative control showing a serial section of 
the third line x600, the red arrow indicates GDNF-positive staining, n=5 per group. (B) Gdnf mRNA expression in whole liver of CCl4, BDL, MCD and 
HFD mice. Bars indicate the mean±SD of three independent experiments; n=5 per group; the t-test with the non-parametric Mann-Whiney U test was 
used. (C) Frozen mouse liver sections on dual α-SMA and GDNF immunohistochemistry (original magnification x100), the lower part represents the 
boxed area with x600 magnification, the green arrow indicates α-SMA and GDNF dual positive staining, n=5 per group.
2219tao l, et al. Gut 2019;68:2214–2227. doi:10.1136/gutjnl-2018-317872
Hepatology
Figure 3 Glial cell line-derived neurotrophic factor (GDNF) overexpression exacerbates carbon tetrachloride (CCl4)-induced liver fibrosis in mice. (A) 
GDNF, α-SMA and Col1 expression examined by immunoblotting and semiquantitative analysis. Liver samples were collected from CCl4-treated mice 
treated with Ad-GDNF or Ad-shuttle vectors (n=5 per group). Representative images of GDNF (B), Sirius red (C) and α-SMA staining and the negative 
control with the same location (D), with the red arrow denoting the α-SMA-positive staining (original magnification, x100). The larger box shows a 
x600 magnification of the small box (n=5 for each group). (E) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in mouse 
serum samples (n=5 per group). mRNA expression of pro-inflammatory cytokines and chemokines (F), as well as fibrogenic parameters (G), examined 
by real-time PCR (n=5 per group). Bars indicate the mean±SD of three independent experiments; n=5 per group; one-way analysis of variance with 
the non-parametric Kruskal-Wallis test was used in parts A, E–G. 
2220 tao l, et al. Gut 2019;68:2214–2227. doi:10.1136/gutjnl-2018-317872
Hepatology
Figure 4 Glial cell line-derived neurotrophic factor (GDNF) induces hepatic stellate cell (HSC) activation in human HSCs. Gdnf mRNA expression 
as determined by real-time PCR. (A) The different types of liver cells were extracted from human liver samples. (B) Gdnf mRNA expression in primary 
HSCs, hepatocyte (HEPs), KCs and liver sinusoidal endothelial cell (LSECs) isolated from olive oil or carbon tetrachloride (CCl4)-treated mice aged 6 
weeks. N.S., not significant. (C) Gdnf mRNA expression in 7-day-culture-activated mouse HSC compared with HEPs, KCs, LSECs and peripheral blood 
mononuclear cells (PBMC) (n=3 per group). (D) Gdnf mRNA expression in cultured human and mouse HSCs at the indicated time points. (E) Real-time 
PCR and western blot analysis for α-SMA and Col1A1. Human and mouse primary HSCs were treated with GDNF (10 ng/mL) for the indicated time 
intervals. (F) Effect of GDNF on fully activated HSCs. GFP-Col-HSCs were plated and cultured in 6-well plates for 2 hours and then treated with GDNF 
(10 ng/mL) for an additional 48 hours; the cells were analysed by fluorescence microscopy (original magnification, x200, n=3) and positive cells were 
counted (%). (G) Western blot analysis for α-SMA and Col1A1. Primary human and mouse HSCs were plated and cultured in 6-well plates overnight, 
followed by si-GDNF or sgGdnf RNA (2 multiple of infection (MOI)) for 48 hours. Bars indicate the mean±SD of three independent experiments; 
n=3 per group; one-way analysis of variance with the non-parametric Kruskal-Wallis test was used in parts A, C and E, and the t-test with the non-
parametric Mann-Whiney U test was used in part B.
HUVEC cells (online supplementary supporting figure 7A). 
We also examined the expression of Gdnf in HSCs, KCs and 
hepatocytes from fibrotic mouse livers, showing upregulation 
in in vivo-activated HSCs from CCl4 and BDL mice, but not 
in KCs and hepatocytes (figure 4B and online supplementary 
supporting figure 7B). In a comparative investigation, we 
showed low Gdnf expression in all cell populations, except 
for activated HSCs (figure 4C).
Gdnf mRNA expression increased over time in primary 
human and mouse HSCs during culture activation (figure 4D). 
To investigate the response of HSCs to GDNF stimulation, 
we treated both hHSCs and mHSCs with recombinant GDNF 
(10 ng/mL), which significantly increased α-SMA and Col1A1 
mRNA and protein levels (figure 4E and F). In contrast, 
α-SMA and Col1 levels decreased on Gdnf sgRNA treatment 
(figure 4G).
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ret, but not GFrα1, via AKT and Smad2/3 downstream 
signalling participate in GDnF-induced culture activation of 
HSC
Mitogen-activated protein kinases participate in GDNF classical 
signalling.21 22 By immunoblotting, we demonstrated with that 
AKT but not ERK was phosphorylated in response to GDNF in 
hHSCs (figure 5A), mHSCs (figure 5B) and LX2 cells (online 
supplementary supporting figure 8A). α-SMA and Col1 protein 
levels were not increased following GDNF stimulation in hHSCs 
and LX2 cells when AKT expression was depleted with small 
interfering RNA (siRNA) or AKT signalling was blunted with 
a specific inhibitor; these results indicate that AKT participates 
in fibrogenic GDNF signalling (figure 5C, D and online supple-
mentary supporting figure 8B, C).
Canonical GDNF signalling is initiated by binding to GFRα1. 
This complex then binds to and activates the transmembrane 
receptor Ret.15 Therefore, we wanted to determine whether 
GFRα1 and Ret are the receptors required for GDNF-induced 
HSC activation. To validate this proposition, we selectively 
inhibited GFRα1 and Ret, using GFRα1-specific siRNA and 
RPI-1, a compound Ret inhibitor and measured the impact on 
activation in hHSC and LX2 cells. Notably, pAKT and pSmad2 
protein levels were still increased by GDNF treatment in 
GFRα1-silenced hHSCs and LX2 cells (figure 5E, F and supple-
mentary supporting figure 8D, E), whereas RPI-1-pretreated, 
GDNF-stimulated HSCs had pAKT protein levels similar to 
those of untreated cells. Furthermore, hepatic GFRα1 mRNA 
levels were unchanged in patients with liver fibrosis (figure 5G), 
whereas Ret mRNA expression was significantly higher in F3 and 
F4 stage patients than in F0 patients (figure 5H). These results 
indicate that Ret, but not GFRα1, contributes to GDNF-induced 
HSC activation in vitro.
Because Smad signalling is the predominant profibrogenic 
pathway in HSC, and GDNF is a member of the TGFβ family, 
we examined whether GDNF could activate Smad signalling 
in HSCs. Indeed, both pSmad2 and pSmad3 were significantly 
increased between 1 and 4 hours after GDNF stimulation in 
hHSCs (figure 5I), mHSCs (figure 5J) and LX2 cells (online 
supplementary supporting figure 8F). Using cytoplasmic and 
nuclear cell extraction, we also found that nuclear presence of 
Smad2 and Smad3 increased significantly after GDNF stimula-
tion in hHSCs (figure 5K) and LX2 cells (online supplementary 
supporting figure 8G). Finally, GDNF stimulation did not induce 
α-SMA and Col1A1 at the protein level in HSCs, when Smad2 
and Smad3 were knocked down by RNAi (figure 5L and M).
AlK5 is required for GDnF-mediated HSC activation
ALK5 is the R-Smad that activates the receptor of TGFβ.29 
Since we found, for the first time, that GDNF induces Smad2 
and Smad3 phosphorylation, and since GFRα1 is not involved 
in this process, we wanted to validate whether ALK5 contrib-
utes to the GDNF signalling complex at the cell surface to trans-
duce profibrogenic signalling. We pretreated the cells with the 
ALK5 inhibitor LY2157299 before GDNF stimulation. In this 
setting, induction of α-SMA and Col1A1 protein expression 
was blunted (figure 5N). In line with this finding, induction of 
pAKT and pSmad2 was abrogated in GDNF-treated LX2 cells 
and hHSCs when we inhibited ALK5-dependent signalling by 
SB431542 (another established ALK5 inhibitor) or when we 
decreased ALK5 expression with siRNA (figure 5O, P and online 
supplementary supporting figure 8H, I). These results suggest 
that ALK5 functions as a signalling receptor in GDNF-medi-
ated HSC activation. Accordingly, ALK5 mRNA expression was 
significantly elevated in fibrotic liver of F3 and F4 stage patients 
than F0 patients (p<0.01; figure 5Q), and we could identify 
a positive correlation between ALK5 and GDNF (r=0.8591; 
p<0.0001) in patients with liver fibrosis (figure 5R).
To gain further insight into signalling receptor complex forma-
tion, we used surface plasmon resonance (SPR) to investigate 
the binding affinity of GDNF to the ALK5 receptor. As shown 
in figure 6A, binding of ALK5 to GDNF was dose-dependent, 
exhibiting a fast association-dissociation process. The response 
units at equilibrium were plotted against ALK5 concentrations 
(figure 6B), and the dissociation constant (KD) was calculated by 
non-linear regression suggesting that GDNF binds to ALK5 with 
a KD value of 85.47 nM.
To define how GDNF binds to ALK5, we constructed a virtual 
GDNF-ALK5 structure model (figure 6C), suggesting an electro 
bond interaction between Glu153 of GDNF and His39 of ALK5, 
as well as a hydrogen bond interaction between Tyr156 of GDNF 
and Asp76 of ALK5. Guided by the model, we mutated His39 
and Asp76 of ALK5 to Ala (figure 6D and E) and subsequently 
examined the GDNF/ALK5 interaction by co-immunoprecip-
itation (co-IP). The interaction of GDNF with ALK5 could 
be demonstrated in LX2 cells with ectopic GDNF and ALK5 
expression, and was abrogated by expressing a mutated ALK5 
receptor (figure 6F).
Finally, we confirmed the ALK5, Ret and p-Smad2 interactions 
and participation in GDNF-induced complex formation by co-IP 
experiments (figure 6G). Taken together, data suggest that ALK5 
is the coreceptor of Ret for GDNF-induced HSC activation.
GDnF, AlK5 and α-SMA colocalise in liver fibrosis in humans 
and mice
To investigate the interaction between GDNF and ALK5 during 
HSC activation in human liver fibrosis, we analysed colocalisa-
tion experiments with confocal microscopy (online supplemen-
tary supporting figure 9). GDNF, ALK5 and α-SMA colocalised 
in liver sinusoids of F0 and F1 patients (online supplemen-
tary supporting figure 9). During fibrosis progression, F2–F4 
stage patients displayed a significant increase in numbers of 
α-SMA-positive cells in hepatic lobules and fibrotic septa. 
GDNF-positive and ALK5-positive cell numbers also increased 
in parallel. This result in patients with liver fibrosis was consis-
tent with the increased GDNF and ALK5 expression in mice 
with liver fibrosis (online supplementary supporting figure 10).
GDnF targeting antibody administration inhibits liver fibrosis 
in mice
To test whether targeting GDNF could mitigate the develop-
ment of liver fibrosis, CCl4 mice were treated with anti-GDNF 
blocking antibodies or isotype IgG, starting after 3 weeks, and 
sacrificed the mice 1 week later (figure 7). Administration of 
either antibody no. 1 (Ab1; 400 ng/g BW; Abcam; cat. ab18956), 
Ab2 (400 ng/g BW; Santa Cruz;  cat. sc- 13147) inhibited fibrosis 
and HSC activation (figure 7). These results suggest that 
targeting GDNF could be an attractive therapeutic strategy for 
patients with liver fibrosis.
TGFβ and GDnF activate the GDnF promoter and GDnF 
mrnA expression via Smad2/3
To estimate how GDNF mRNA expression is regulated in HSCs, 
we tested its transcriptional regulation on treatment with TGFβ. 
Indeed, TGFβ induced GDNF mRNA expression in HSCs 
(figure 8A). We also found that Tgfβ and Gdnf mRNA were both 
increased in CCl4-induced liver fibrosis, suggesting that TGFβ 
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Figure 5 Glial cell line-derived neurotrophic factor (GDNF) induces hepatic stellate cell (HSC) activation via the activin receptor-like kinase 5 
(ALK5)/Smad pathway. Western blot analysis for (p-)AKT and (p-)Erk and semiquantification. Human (A) and mouse (B) HSCs were treated with 
GDNF (10 ng/mL) for the indicated time. (C) Western blot analysis for α-SMA and Col1A1. AKT small interfering RNA (siRNA) was transfected into 
human HSCs for 12 hours and then the cells were treated with 10 ng/mL GDNF for an additional 48 hours. (D) Western blot analysis for α-SMA and 
Col1A1. Human HSCs were treated with MK2206 2HCL (0.5 µM) for 1 hour, followed by 10 ng/mL GDNF for an additional 48 hours. (E) Western blot 
analysis for (p-)AKT and (p-)Smad2. Human HSCs were transfected with GFRα1 siRNA for 48 hours and subsequently treated with 10 ng/mL GDNF 
for an additional 2 hours. (F) Western blot analysis for (p-)AKT and (p-)Smad2. Human HSCs were treated with RPI-1 (60 µM) for 1 hour, followed by 
treatment with 10 ng/mL GDNF for additional 2 hours. (G, H) GFRα1 and Ret mRNA expression in 165 human liver specimens. The levels of target 
mRNAs were normalised to that of 18S rRNA (F0=13; F1=35; F2=61; F3=40; F4=16). (I, J) Western blot analysis for (p-)Smad2 and (p-)Smad3 and 
semiquantification. Human (I) and mouse (J) HSCs were treated with GDNF (10 ng/mL) as indicated. (K) Western blot analysis for Smad2 and Smad3. 
Human HSCs were treated with GDNF (10 ng/mL) for 2 hours, and nuclear and cytoplasmic extracts were tested for Smad2/3 levels. (L, M) Western 
blot analysis for α-SMA and Col1A1. Human HSCs were transfected with siRNA for Smad2 or Smad3 for 12 hours and then treated with GDNF (10 ng/
mL) for additional 48 hours. (N) Western blot analysis for α-SMA and Col1A1. Human HSCs were treated with LY2157299 (0.5 µM) for 1 hour and then 
GDNF (10 ng/mL) for an additional 48 hours. (O) Western blot analysis for (p-)AKT and (p-)Smad2. Human HSCs were treated with SB431542 (10 µM) 
for 1 hour and then GDNF (10 ng/mL) for an additional 2 hours. (P) Western blot analysis for (p-)Smad2 and (p-)Smad3. Human HSCs were transfected 
with ALK5 siRNA for 12 hours and then GDNF (10 ng/mL) for an additional 48 hours. (Q, R) mRNA expression of ALK5 in 165 human liver specimens. 
The level of ALK mRNAs was normalised to that of 18S rRNA (F0=13; F1=35; F2=61; F3=40; F4=16). Correlation analysis between ALK5 and GDNF 
mRNA expression in patients with liver fibrosis. Spearman's correlation coefficients (r), p values and the number of patients are indicated. Bars 
indicate the mean±SD of three independent experiments; n=3 per group; one-way analysis of variance with the non-parametric Kruskal-Wallis test 
was used in parts A, B, G–I, J and K, and the non-parametric correlation (Spearman's) two-tailed test was used in part R.
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Figure 6 Determination of two critical sites of activin receptor-like kinase 5 (ALK5) for glial cell line-derived neurotrophic factor (GDNF) 
binding. (A) The binding affinity of GDNF to ALK5 was determined using surface plasmon resonance (SPR). (B) The dissociation constant (KD) of 
GDNF and ALK5 was calculated by non-linear regression analysis. GDNF bound to ALK5 with a KD value of 85.47 nM. (C) The complex of ALK5 
and GDNF was generated by in silico estimation using a rigid-body docking approach with PatchDock software (http://bioinfo3d.cs.tau.ac.il/
PatchDock/). (D) Expression plasmid sequences of ALK5-wt and ALK5-mut were validated. (E) ALK5-wt and ALK5-mut amino acid sequences. (F) co-
immunoprecipitation (co-IP) analysis of ALK5/GDNF interaction comparing wt and His39 and Asp76 mutated ALK5. LX2 cells were transfected with 
pcDNA3-ALK5 plasmids for 12 hours and subsequently treated with Ad-GDNF for an additional 48 hours. (G) Direct interaction of ALK5 with Ret after 
GDNF stimulation. After IP with an anti-ALK5 antibody, immunoblotting for Ret was performed. (H) Direct interaction of ALK5 with p-Smad2 after 
GDNF stimulation. After IP with an anti-ALK5 antibody, immunoblotting for p-Smad2 was performed.
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Figure 7 Administration of anti-glial cell line-derived neurotrophic factor (anti-GDNF) antibodies reduces liver fibrosis development in mice. (A) 
Anti-GDNF-blocking antibodies blunted carbon tetrachloride (CCl4)-induced liver injury (intraperitoneal injections; Ab1: 400 ng/g BW; Ab2: 400 ng/g 
BW administered for 3 weeks (once a week), starting from the second week after CCl4 treatment); controls were treated with IgG (400 ng/g BW). 
(B, C) Sirius red and α-SMA staining (original magnification, ×100). The positive stained area was calculated as a percentage. Col1α1 and α-Sma 
mRNA expression levels are shown as the fold downregulation in comparison to untreated animals. Bars indicate the mean±SD of three independent 
experiments; n=6 per group; one-way analysis of variance with the non-parametric Kruskal-Wallis test was used in parts A–C.
might be the initial inducer of GDNF expression in liver fibrosis 
(figure 8B). GDNF mRNA was not induced in response to TGFβ 
or GDNF stimulation, when Smad2/3 were knocked down by 
siRNA (figure 8C). These results indicate that Smad2/3 is required 
for GDNF mRNA upregulation during HSCs activation. Bioin-
formatics analysis of the human GDNF promoter revealed that 
the −60 to −46 site contained a Smad2/3 binding sequence. We 
experimentally confirmed Smad2/3 binding by chromatin immu-
noprecipitation (ChIP) assays (figure 8D). Furthermore, Smad2 
and Smad3 expression levels were upregulated in fibrotic liver of 
patients (figure 8E, F), and were correlated with GDNF expres-
sion. Taken together, our data strongly suggest that GDNF facil-
itates liver fibrosis progression via Ret and ALK5 receptors and 
Akt/Smad2/3 pathways (figure 8G).
DISCuSSIOn
Liver fibrosis involves several key factors, including HSC acti-
vation and profibrogenic signal transduction.30 31 In this study, 
we show that GDNF levels increase in chronic liver diseases 
in human and mouse. Our data reveal a novel mechanism of 
GDNF-induced HSC activation via the TGFβ receptor ALK5. 
We also discovered colocalisation of GDNF, ALK5 and α-SMA 
in liver of patients and mice with fibrosis. Administration of 
GDNF-blocking antibodies attenuated CCl4-induced liver 
fibrosis in mice, suggesting that GDNF could serve as an attrac-
tive target for antifibrotic therapy.
GDNF is well known as a trophic factor in neural cells (see 
online supplementary supporting discussion). In addition to 
the brain, the function of GDNF has been studied in other 
diseases. Currently, there is limited knowledge about its role in 
liver injury. It was recently reported that GDNF is protective in 
HFD-induced insulin resistance, hyperlipidemia and obesity in 
mice.32 33 In their experiments, Mwangi et al used transgenic 
GDNF expression in mice, and investigated GDNF responses of 
hepatocytes in experimental NAFLD. They convincingly showed 
that in the setting of hepatocyte steatosis, GDNF is protective 
through the downregulation of peroxisome proliferator-acti-
vated receptor-γ (PPAR-γ) expression. In HSCs, however, down-
regulation of PPAR-γ is required for activation, and thus is in line 
with a profibrogenic role of GDNF.34 In total, we demonstrated 
that serum GDNF concentrations were significantly higher 
in 239 patients with liver disease as compared with 127 HCs 
with a positive correlation to the fibrotic stage. GDNF expres-
sion in liver was remarkably higher in F3 and F4 stage than in 
F0 stage patients. We further showed that the liver itself was 
producing GDNF in advanced liver fibrosis, mainly in HSCs 
and demonstrated that hepatic GDNF mRNA and protein levels 
were increased in F2/F3/F4 stage patients with NASH. Human 
data could also be validated in mouse MCD and HFD NAFLD 
models. With that, we are first to determine HSCs as responsible 
cell type expressing GDNF in liver.
HSCs have been frequently described as relatives of glial or 
neuronal cells, since they express several respective markers, 
for example, glial fibrillary acidic protein (GFAP),35 neurotro-
phins and their receptors, including nerve growth factor (NGF), 
brain-derived neurotrophic factor, neurotrophin 4/5 and NGF 
receptor p75.36 Given the findings of the present study, we can 
now also add GDNF to this list as a neuronal marker protein 
expressed by stellate cells. Moreover, in response to this cyto-
kine, GDNF increases α-SMA and Col1A1 expression in HSCs 
and, therewith, mediates HSC activation.
Despite the physiological and clinical significance of GDNF, 
the signalling pathway activated by GDNF has not yet been 
fully elucidated. Biochemical and cell culture studies suggest 
that GDNF binds to GFRα1 requiring the transmembrane tyro-
sine kinase Ret14 to form a functional receptor complex. Both 
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Figure 8 The glial cell line-derived neurotrophic factor (GDNF)/activin receptor-like kinase 5 (ALK5)/Ret/Smad2/3 circuit promotes hepatic stellate 
cell (HSC) activation. (A) Real-time PCR Gdnf mRNA detection after transforming growth factor-β (TGFβ) treatment in human and mouse HSCs. 
(B) Real-time PCR for Tgfβ and Gdnf mRNA in carbon tetrachloride (CCl4)-induced liver fibrosis. (C) GDNF mRNA was not induced in response to 
TGFβ and GDNF stimulation, when Smad2/3 were depleted using specific small interfering RNAs in LX2 cells. (D) Schematic diagram of the putative 
Smad2/3 binding site within the human GDNF promoter. LX2 cells were subjected to ChIP assays with anti-Smad2/3 or IgG antibodies. Representative 
results from three independent experiments are shown. mRNA expression of Smad2 (E) and Smad3 (F) in 165 human liver specimens. The levels of 
Smad2/3 mRNAs were normalised to that of 18S rRNA (F0=13; F1=35; F2=61; F3=40; F4=16). Correlation analysis between Smad2/3 and GDNF 
mRNA expression in patients with liver fibrosis. Spearman's correlation coefficients (r), p values and the number of patients are indicated. Bars 
indicate the mean±SD of three independent experiments; n=3 per group; the t-test with the non-parametric Mann-Whiney U test was used in part A, 
one-way analysis of variance with the non-parametric Kruskal-Wallis test was used in parts C and E, and the non-parametric correlation (Spearman's) 
two-tailed test was used in parts E and F. (G) Graphical summary of GDNF fibrogenic signalling in HSCs. HSCs express the GDNF receptors GFRα1 
and Ret, whereas only Ret is upregulated in patients with liver fibrosis. GDNF induces AKT and Smad2/3 phosphorylation as a short-term response. 
As downstream events, GDNF induces GDNF transcription as an autocrine feedback stimulation and fibrogenic gene expression, as exemplified by 
α-SMA and Col1. ALK5 and Ret, but not GFRα1, are required for AKT/Smad2/3 activation and subsequent GDNF and α-SMA/Col1 expression. ALD, 
alcoholic liver disease; NASH, non-alcoholic steatohepatitis.
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proteins are coexpressed in the developing nephron, midbrain 
and motor neurons and mice carrying a disruption of either 
Ret or GFRα1 are deficient in renal and neuronal development 
and suffer from early postnatal death.15 GDNF/Ret signal-
ling through the phosphatidylinositol 3-kinase/nuclear factor 
kappa B pathway is required for mitochondrial function and 
morphology,37 and seems also relevant for dopamine system 
maintenance to prevent Parkinson's and Hirschsprung diseases.22 
Besides, it has been reported that p140NCAM may interact with 
GFRα1 to mediate GDNF signalling independently from Ret 
in Schwann cell migration.38 Another study also describes that 
GDNF can regulate migration of GABAergic cells in the medial 
ganglionic eminence and cortex via GFRα1, but not Ret or 
NCAM.20 Finally, an inverse relationship between GFRα1 and 
Ret has been reported in dopaminergic neurons, where knocking 
down Ret leads to increased GFRα1 expression.23
In HSC, GDNF induces activation through Smad2/3 and AKT 
signalling. Our data showed that only Ret but not GFRα1 was 
required for GDNF-induced HSC activation. In line with these 
in vitro data, Ret mRNA levels were significantly elevated in F3 
and F4 stage compared with F0 stage patients, where GFRα1 
levels were not significantly changed. Because GFRα1 was not 
involved in the identified activation-related GDNF signalling in 
HSC, we wanted to identify a coreceptor of Ret in this cell type. 
GDNF is a member of the TGFβ superfamily and we found that 
it could induce HSC activation. TGFβ is mediating its multi-
functional effects on liver cells by binding to ALK539 40 followed 
by subsequent downstream signalling via phosphorylation and 
nuclear translocation of Smad2/3 to regulate target gene expres-
sion in a context-dependent manner.41 Thus, we hypothesised 
that GDNF might involve ALK5 to induce HSC activation. 
Indeed, HSC activation in response to GDNF was suppressed 
by the ALK5 inhibitors SB451342 and LY2157299. Further-
more, SPR analysis, the gold standard method for studying 
protein-protein interactions, confirmed that GDNF bound to 
ALK5. After mutating Asp76 and His39 to Ala in recombinant 
ALK5 protein, which are the obvious critical binding sites as 
determined by computer simulation, the binding of GDNF and 
ALK5 was blunted, as measured by co-IP analysis. Considering 
these results, we concluded that ALK5 participates in GDNF-in-
duced HSC activation. To the best of our knowledge, this is the 
first report to show that GDNF can induce HSC activation via 
the ALK5/Smad pathway. Finally, we confirmed the correlation 
between GDNF, ALK5 and α-SMA in liver fibrosis by colocalisa-
tion studies in humans with tricolour laser confocal microscopy.
In conclusion, our results show that GDNF is significantly 
upregulated in human liver fibrosis and is produced by HSCs. 
GDNF can induce HSC activation via Ret/ALK5 receptors 
and the AKT and Smad pathways. Blocking GDNF can inhibit 
fibrosis progression. Based on these findings, GDNF could be an 
attractive therapeutic target for the treatment of liver fibrosis in 
the future.
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